Financing
Google spinout Verily has raised $300m to advance its AI-driven personalized healthcare platforms and become an independent company.
Payers' and patients' growing preference for outpatient care is increasing pressure on private providers to continually reassess how they deliver value. Jean-Philippe Grosmaitre and Guillaume Duparc, partners at L.E.K. Consulting, outlined growth opportunities available to private hospitals.
Kanaph Therapeutics and IMbiologics launched successful offerings in the IPO-scarce Korean market in the first quarter, as investors become more selective in their targets.
Nine $1bn+ alliances were penned in February, and three exceeded $2bn. In the top alliance by deal value, Innovent Biologics entered into a potential $8.85bn collaboration with Eli Lilly to advance novel medicines in oncology and immunology.
Bond issuance and extended revolving credit facility provide financial headroom as the company restructures operations to accelerate biosimilars growth while maintaining generics scale.
Seed investors are enthusiastic about AI in drug discovery but skeptical of the valuations it is used to justify. At a recent panel, they drew a sharp line between real capability and an “AI veneer.”
Deal after deal, Formycon was inching toward closing the gap in its annual guidance. Still, it was not enough to meet the goal, as the German biosimilars developer’s preliminary financial report reveals.
An interactive look at medtech and diagnostics deals made during February 2026. Data courtesy of Biomedtracker.
Industry leaders share how Britain can strengthen its biotech ecosystem, from capital and regulation to talent and ambition, and what the sector could look like by 2030.
An interactive look at pharma, medtech and diagnostics deals made during February 2026. Data courtesy of Biomedtracker.
South Korea's government is expanding initiatives to attract clinical trials, foreign pharma investment and partnerships as it looks to support domestic firms' R&D and international expansion ambitions.
A decade ago, China was buying Western drugs. Now it is selling them. Executives who ignore the shift do so at their peril.